How should drug dosing be determined for a patient, considering age, weight, renal and hepatic function, and comorbidities?

Drug Dosing Determination in Clinical Practice

Drug dosing must be systematically adjusted based on renal function (using CKD-EPI equation), age-related physiologic changes, and specific drug pharmacokinetic properties, with renal function being the single most critical factor for dose modification.

Primary Dosing Framework

The foundation of appropriate drug dosing rests on three sequential assessments:

1. Renal Function Assessment (Most Critical)

Always calculate estimated glomerular filtration rate (eGFR) using the CKD-EPI equation 1, which is more accurate than creatinine-based equations alone in older adults. Serum creatinine can be misleadingly normal in elderly patients despite significant renal impairment due to reduced muscle mass 2.

For renally cleared medications, dosing adjustments follow this hierarchy 3:

• Creatinine clearance <50 mL/min: Reduce dosing frequency or dose amount
• Creatinine clearance 10-30 mL/min: Further dose reduction required (often to 50% of standard dose)
• Creatinine clearance <10 mL/min: Many medications should be avoided entirely 4

Critical principle: For concentration-dependent drugs (aminoglycosides, fluoroquinolones), maintain the milligram dose but extend the dosing interval to 2-3 times weekly rather than reducing individual doses 3. This preserves efficacy while preventing accumulation.

2. Age-Related Modifications

For patients >65 years 5, 6, 7:

• Renal function declines by approximately 1% per year after age 30-40, meaning a 70-year-old may have 40% reduced renal function even with "normal" creatinine 2
• For patients >75 years: Start with reduced initial doses (e.g., dexamethasone 20 mg weekly instead of standard dosing) 8
• For patients >59 years: Injectable antibiotics (streptomycin, amikacin, kanamycin, capreomycin) should be reduced to 10 mg/kg/day (maximum 750 mg) 3

Hepatic metabolism changes with age 1:

• Drugs with high hepatic extraction (diltiazem, metoprolol, propranolol, verapamil) require dose reduction due to decreased hepatic blood flow
• Phase I metabolism (CYP450) decreases 20-50%, while Phase II conjugation remains relatively preserved

3. Weight-Based Dosing Considerations

For obesity 9:

• Aminoglycosides: Use adjusted body weight (ABW) for initial dosing: ABW = IBW + 0.4(TBW - IBW), where IBW = ideal body weight, TBW = total body weight
• Loading doses: Base on total body weight for lipophilic drugs; use adjusted weight for hydrophilic drugs
• Maintenance doses: Guide by therapeutic drug monitoring rather than weight alone

For children 10, 11:

• Age <2 months: Extreme caution with hepatically metabolized drugs; base dosing on response and therapeutic drug monitoring
• Age 2-6 months: Use weight-based dosing (mg/kg)
• Age >6 months: Body surface area (BSA) becomes the preferred metric, except for CYP2D6 substrates which should remain weight-based
• Hydrophilic drugs with high Vd: Normalize to body weight in children <2 years
• Hydrophilic drugs with low Vd: Normalize to BSA in children <2 years

Specific High-Risk Medications Requiring Adjustment

Medications to Avoid Below Specified Renal Function 4:

• CrCl <30 mL/min: Chlorpropamide, glyburide, meperidine, nitrofurantoin, propoxyphene
• CrCl <10 mL/min: Colchicine, cotrimoxazole, probenecid, spironolactone, triamterene

Medications Requiring Specific Dose Reduction 5, 10, 4:

Amantadine:

• Age >65 years: Maximum 100 mg/day
• CrCl <50 mL/min: Consult package insert for specific adjustments

Rimantadine:

• Age >65 years: 100 mg/day (not 200 mg/day)
• CrCl <10 mL/min: 100 mg/day

Oseltamivir (by weight in children) 10:

• ≤15 kg: 30 mg twice daily

• 15-23 kg: 45 mg twice daily

• 23-40 kg: 60 mg twice daily

• 40 kg: 75 mg twice daily

• Renal adjustment: CrCl 10-30 mL/min: 75 mg once daily for treatment

Critical Pitfalls to Avoid

1. Never rely on serum creatinine alone in elderly patients—it underestimates renal impairment 2, 1

2. For injectable antibiotics with nephrotoxicity/ototoxicity risk (aminoglycosides, capreomycin): Dose after dialysis, maintain mg/kg dose but extend interval, and monitor serum concentrations 3

3. Avoid these combinations in elderly with renal impairment 4:

   • Spironolactone + ACE inhibitors/ARBs (hyperkalemia risk)
   • Glyburide in any degree of renal impairment (hypoglycemia risk)

4. For drugs with narrow therapeutic index (chemotherapy, aminoglycosides, vancomycin): Therapeutic drug monitoring is mandatory, not optional 2, 8

Practical Dosing Algorithm

Step 1: Calculate eGFR using CKD-EPI equation (not Cockcroft-Gault in elderly) 1

Step 2: Identify primary elimination route:

• Renal: Adjust based on eGFR
• Hepatic: Consider age-related hepatic blood flow changes
• Mixed: Adjust for both

Step 3: Determine loading vs. maintenance dose needs:

• Loading dose: Based on volume of distribution (consider age, weight, hydration)
• Maintenance dose: Based on clearance (primarily renal function)

Step 4: For high-risk drugs, implement therapeutic drug monitoring from the start 12

Step 5: Reassess renal function regularly—it changes with acute illness, hydration status, and concurrent nephrotoxic medications 2